It had a disappointing start, though, and this was borne financials in the second quarter. While Qsymia prescriptions by 37% over the previous quarter, it translates into a mere $ 5.5 million in sales, and Vivus spent $ 52.5 million during the quarter. All these scripts were four certified mail-order pharmacies, an annoying FDA requirement that filled since been repealed.

Vivus recently suffered a mutiny by the way, a difficult fight, zixiutang bee pollen capsules and one proxy in favor of its 9.9% First Investor Manhattan FMC Corp. was settled insisted on the lintel of the top management and the creation of a new 11-member board including Zook AstraZeneca plc, a former executive who successfully brought to market various drugs. The new board has been carefully selected, FMC said to help with the necessary know-how for the turnaround. Only one of the four non-FMC-elected board members, Mark Logan, was appointed before April, when FMC began his activist campaign.

However, as the proxy battle raged, Vivus began to start making progress in his Qsymia. The company has more than 10,000 certified pharmacies, including national and retail chains such as Walgreen Co. zixiutang and Duane Reade Inc. Independent pharmacies signed on board to come in the fourth quarter, the company said. Along with the expansion of access to retail, the company has worked with insurers to reduce payments to a consumer-friendly $ 25 to $ 35, from the previous 50 € to $ 65 range.